New hope for rare immune storm: experimental drug targets severe MAS
NCT ID NCT07208058
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests an experimental drug called plonmarlimab in 30 people aged 16 to 80 who have a rheumatic disease and a severe immune overreaction known as MAS that has not responded to prior treatments. The goal is to see if the drug can control the overactive immune system and improve outcomes. Participants receive the drug and are monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY RHEUMATIC AND IMMUNOLOGIC DISEASE-ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
Children's Hospital of Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Children's Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact
-
Huashan Hospital, Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Peking University People's Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
Contact
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact
-
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, China
Contact
-
Tianjin Medical University General Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.